Canadian pharmaceutical development company Algernon Pharmaceuticals has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of DMT – AP-188 – in...
A quantum drug development programme has been launched by psychedelic healthcare company PsiloThera.